- Home
- HUIZ vs RNTX Comparison
HUIZ vs RNTX Comparison
Compare HUIZ & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUIZ
- RNTX
- Stock Information
- Founded
- HUIZ 2006
- RNTX 2001
- Country
- HUIZ China
- RNTX United States
- Employees
- HUIZ N/A
- RNTX N/A
- Industry
- HUIZ Specialty Insurers
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- HUIZ Finance
- RNTX Health Care
- Exchange
- HUIZ Nasdaq
- RNTX Nasdaq
- Market Cap
- HUIZ 25.3M
- RNTX 28.0M
- IPO Year
- HUIZ 2020
- RNTX N/A
- Fundamental
- Price
- HUIZ $3.06
- RNTX $1.15
- Analyst Decision
- HUIZ Hold
- RNTX Hold
- Analyst Count
- HUIZ 1
- RNTX 1
- Target Price
- HUIZ $2.30
- RNTX N/A
- AVG Volume (30 Days)
- HUIZ 721.2K
- RNTX 133.3K
- Earning Date
- HUIZ 09-12-2025
- RNTX 11-13-2025
- Dividend Yield
- HUIZ N/A
- RNTX N/A
- EPS Growth
- HUIZ N/A
- RNTX N/A
- EPS
- HUIZ 0.25
- RNTX N/A
- Revenue
- HUIZ $186,519,166.00
- RNTX N/A
- Revenue This Year
- HUIZ $11.94
- RNTX N/A
- Revenue Next Year
- HUIZ $8.15
- RNTX N/A
- P/E Ratio
- HUIZ $15.34
- RNTX N/A
- Revenue Growth
- HUIZ 19.12
- RNTX N/A
- 52 Week Low
- HUIZ $1.50
- RNTX $1.04
- 52 Week High
- HUIZ $10.58
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- HUIZ 53.66
- RNTX 45.62
- Support Level
- HUIZ $2.70
- RNTX $1.07
- Resistance Level
- HUIZ $4.53
- RNTX $1.25
- Average True Range (ATR)
- HUIZ 0.30
- RNTX 0.14
- MACD
- HUIZ 0.09
- RNTX -0.01
- Stochastic Oscillator
- HUIZ 28.99
- RNTX 21.33
About HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.